Aytu BioPharma (NASDAQ:AYTU – Get Free Report) was downgraded by analysts at Lake Street Capital from a “buy” rating to a “hold” rating in a research note issued on Tuesday, MarketBeat reports. They presently have a $2.70 price objective on the stock. Lake Street Capital‘s target price points to a potential upside of 48.35% from the stock’s previous close.
Several other research analysts also recently issued reports on AYTU. Weiss Ratings downgraded Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th. Citigroup reissued a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Finally, Zacks Research cut Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.60.
Check Out Our Latest Report on AYTU
Aytu BioPharma Stock Performance
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.06. The company had revenue of $14.84 million for the quarter, compared to the consensus estimate of $13.27 million. Aytu BioPharma had a negative net margin of 24.76% and a negative return on equity of 56.54%. As a group, research analysts predict that Aytu BioPharma will post -0.16 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Nantahala Capital Management LLC purchased a new position in shares of Aytu BioPharma during the 2nd quarter worth $2,336,646. Stonepine Capital Management LLC purchased a new stake in shares of Aytu BioPharma in the second quarter valued at $1,962,780. AWM Investment Company Inc. purchased a new stake in shares of Aytu BioPharma in the second quarter valued at $1,332,000. BlackRock Inc. purchased a new stake in shares of Aytu BioPharma in the second quarter valued at $49,000. Finally, Crown Advisors Management Inc. acquired a new position in Aytu BioPharma in the second quarter valued at $430,000. 33.49% of the stock is currently owned by institutional investors and hedge funds.
Latest Aytu BioPharma News
Investors following AYTU have been watching these news items:
- Positive Sentiment: Rosemont agreed to acquire Aytu in an all-cash tender offer valued at $2.70 per share. The agreed price gives investors a defined cash consideration if the transaction closes, and Rosemont says the deal will support its U.S. expansion. Completion remains subject to the agreement’s conditions. Rosemont acquisition announcement
- Positive Sentiment: Fiscal 2027 first-quarter revenue was $14.84 million, above analysts’ $13.27 million estimate, providing a favorable operating result alongside the acquisition news. Aytu quarterly results
- Neutral Sentiment: Quarterly results were mixed: Aytu reported a loss of $0.20 per share, compared with a $0.08 loss a year earlier. Fiscal 2027 first-quarter results
Aytu BioPharma Company Profile
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.
Featured Stories
- Five stocks we like better than Aytu BioPharma
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
